Kairos Pharma Ltd
Research Kairos Pharma Ltd (KAPA) on Bullrun: market cap USD 5.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKAPA
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.31M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.84M
- Free cash flow-USD 3.76M
Valuation Snapshot
latest market cap is USD 5.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 5.45M | -USD 3.44M | n/a | -0.3 | USD 4.49M | n/a | USD 6.34M |
| FY2024 | USD 0 | -USD 2.60M | -USD 3.96M | n/a | -0.23 | USD 1.27M | USD 142.00K | USD 4.78M |
| FY2023 | n/a | -USD 1.81M | n/a | n/a | -0.17 | USD 93.00K | USD 638.00K | -USD 2.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.78M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 20.88M | n/a | n/a | n/a |
About Kairos Pharma Ltd
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kairos Pharma Ltd's market cap?
Kairos Pharma Ltd's market capitalization is USD 5.31M.
What does Kairos Pharma Ltd do?
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer.